Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Effect of Adding l -Carnitine to Risperidone on Behavioral, Cognitive, Social, and Physical Symptoms in Children and Adolescents With Autism: A Randomized Double-Blinded Placebo-Controlled Clinical Trial.

  • 2023-02-04
  • Clinical neuropharmacology 46(2)
    • Fereshteh Shakibaei
    • Danial Jelvani

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 25
Population
50 ASD children and adolescents
Methods
randomized controlled clinical trial; l-carnitine and risperidone versus placebo and risperidone for 8 weeks
Duration
8 weeks
Funding
Unclear

Objectives

The present research aimed to evaluate the effect of adding l -carnitine to risperidone in treating children and adolescents with autism spectrum disorder (ASD).

Methods

In this randomized controlled clinical trial study, 50 ASD children and adolescents were divided into 2 groups: those receiving l -carnitine and risperidone (n = 25) and those receiving placebo and risperidone (n = 25). Treatment continued for 8 weeks, and participants were assessed at the beginning of the study, in the fourth and eighth weeks, by the Aberrant Behavior Checklist (ABC).

Results

l -Carnitine add-on therapy reduced the scores of total ABC and subscales of restlessness, lethargy and social isolation, stereotypic behavior, and inappropriate speech at weeks 4 and 8. There was a significant difference between the 2 groups in the score of total ABC and subscale of lethargy and social isolation.

Conclusions

According to the present study, adding l -carnitine to risperidone improves ASD symptoms.

Research Insights

Back to top